“This 2023 edition of the ESMO meeting once again conveys the momentum and quality of the clinical research conducted at Institut Curie“, enthuses Prof. Steven Le Gouill, director of the Hospital Group at Institut Curie. “The combination of our expertise in certain locations with high-level research has brought our teams to the forefront of European oncology, with increasingly innovative and promising approaches for patients“.
– L’essentiel –
Bispecific antibodies/ New effective strategies in rare lung cancer and metastatic uveal melanoma
Epidrugs/ Towards new innovative anti-cancer therapies: promising results from the combination of an epidrug and immunotherapy in squamous cell carcinoma
Nanoparticles/ A new milestone reached in ENT cancers for a unique and original class of drugs |